PortalPublikationenFinal results of a phase I/II pilot study of capecitabine wi...

Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer.

Standard

Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer. / Müller, Volkmar; Thomssen, Christoph; Schmidt, Marcus; Glados, Manfred; Jackisch, Christian; Heilmann, Volker; Hinke, Axel; Lehnert, Antje; Borowicz, Henryk; Möbus, Volker.

in: BMC CANCER, Jahrgang 10, 2010, S. 430.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Müller, V, Thomssen, C, Schmidt, M, Glados, M, Jackisch, C, Heilmann, V, Hinke, A, Lehnert, A, Borowicz, H & Möbus, V 2010, 'Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer.', BMC CANCER, Jg. 10, S. 430. https://doi.org/10.1186/1471-2407-10-430

APA

Müller, V., Thomssen, C., Schmidt, M., Glados, M., Jackisch, C., Heilmann, V., Hinke, A., Lehnert, A., Borowicz, H., & Möbus, V. (2010). Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer. BMC CANCER, 10, 430. https://doi.org/10.1186/1471-2407-10-430

Vancouver

Müller V, Thomssen C, Schmidt M, Glados M, Jackisch C, Heilmann V et al. Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer. BMC CANCER. 2010;10:430. https://doi.org/10.1186/1471-2407-10-430

Bibtex

@article{6a763c448f6f4a54b1ace5bc241de0eb,
title = "Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer.",
abstract = "The integration of the non-cross-resistant chemotherapeutic agents capecitabine and vinorelbine into an intensified dose-dense sequential anthracycline- and taxane-containing regimen in high-risk early breast cancer (EBC) could improve efficacy, but this combination was not examined in this context so far.",
author = "Volkmar M{\"u}ller and Christoph Thomssen and Marcus Schmidt and Manfred Glados and Christian Jackisch and Volker Heilmann and Axel Hinke and Antje Lehnert and Henryk Borowicz and Volker M{\"o}bus",
year = "2010",
doi = "10.1186/1471-2407-10-430",
language = "Deutsch",
volume = "10",
pages = "430",
journal = "BMC CANCER",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer.

AU - Müller, Volkmar

AU - Thomssen, Christoph

AU - Schmidt, Marcus

AU - Glados, Manfred

AU - Jackisch, Christian

AU - Heilmann, Volker

AU - Hinke, Axel

AU - Lehnert, Antje

AU - Borowicz, Henryk

AU - Möbus, Volker

PY - 2010

Y1 - 2010

N2 - The integration of the non-cross-resistant chemotherapeutic agents capecitabine and vinorelbine into an intensified dose-dense sequential anthracycline- and taxane-containing regimen in high-risk early breast cancer (EBC) could improve efficacy, but this combination was not examined in this context so far.

AB - The integration of the non-cross-resistant chemotherapeutic agents capecitabine and vinorelbine into an intensified dose-dense sequential anthracycline- and taxane-containing regimen in high-risk early breast cancer (EBC) could improve efficacy, but this combination was not examined in this context so far.

U2 - 10.1186/1471-2407-10-430

DO - 10.1186/1471-2407-10-430

M3 - SCORING: Zeitschriftenaufsatz

VL - 10

SP - 430

JO - BMC CANCER

JF - BMC CANCER

SN - 1471-2407

ER -